ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,472,175, issued on Nov. 18, was assigned to Oregon Health & Science University (Portland, Ore.).
"Methods of treating venetoclax-resistant acute myeloid leukemia" was invented by Jeffrey Tyner (Portland, Ore.), Tamilla Nechiporuk (Portland, Ore.), Stephen Kurtz (Portland, Ore.) and Shannon McWeeny (Portland, Ore.).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention concerns novel methods of treatment for venetoclax-resistant acute myeloid leukemia, particularly in subjects with a low expression of TP53 protein or expression of TP53 protein associated with a mutation of the TP53 gene, the methods comprising administering to the subject in...